---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-009846"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:59:13.106598+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Perspective Therapeutics provides VMT-α-NET and pipeline updates; 76% progression-free in NET trial

## Summary
- VMT-α-NET Cohort 2: 19/25 pts (76%) progression-free at median ~13 wks additional follow-up vs ESMO 2025; 9/23 (39%) had RECIST response.
- Safety in 56 pts: no DLTs, no treatment-related discontinuations; Grade 3+ AEs in 37.5%, one transient Grade 4 lymphopenia.
- Cohort 3 (6.0 mCi) cleared by SMC after 8-patient DLT review; 9 patients treated as of Dec 31, 2025.
- VMT01 melanoma: 9 patients dosed at 3.0 mCi (5 with nivolumab, 4 monotherapy) as of Dec 31; data submission planned after 24-week follow-up.
- PSV359 FAP-targeting trial: 5 patients dosed across Cohort 1 (2.5 mCi) and Cohort 2 (5.0 mCi) with site activations underway.

## SEC filing metadata
- accession: 0001193125-26-009846
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000119312526009846/0001193125-26-009846-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000119312526009846/catx-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-009846
- JSON: https://secwatch.observer/filing/0001193125-26-009846.json
- Plain text: https://secwatch.observer/filing/0001193125-26-009846.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.